Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22254206 | 0.88 | ROCK2 (0.39) | ROCK2ACVR1KDM4EALDH1A1 | |
| SCHEMBL25553665 | 0.88 | ROCK2 (0.39) | ROCK2ACVR1KDM4EALDH1A1 | |
| SCHEMBL22254391 | 0.88 | KDM1A (0.36) | ROCK2ACVR1POLB | |
| SCHEMBL25532341 | 0.88 | KDM1A (0.36) | ROCK2ACVR1POLB | |
| SCHEMBL25532052 | 0.85 | ROCK2 (0.37) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL22254220 | 0.85 | ROCK2 (0.37) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL22233893 | 0.83 | ROCK2 (0.51) | ROCK2KDM4EPOLBMAPK14SMYD3 | |
| SCHEMBL22233519 | 0.83 | ROCK2 (0.36) | ROCK2KDM4EALDH1A1 | |
| SCHEMBL22233618 | 0.81 | KDM4E (0.31) | KDM4EALDH1A1GHSRMAPK14 | |
| SCHEMBL22254236 | 0.81 | ROCK2 (0.38) | ROCK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | ROCK2 2850/4885ACVR1 4858/4885KDM4E 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.